Anne Wojcicki still wants her 23andMe. This time, she is requesting that the auction be reopened for more bids–hers, along with a new backer. The unnamed “Fortune 500 company with a current market ...

Takeaways: other insurers are challenged but UHG, for 40 years the best managed of the lot, is stumbling and falling into a hole; it hasn’t moved beyond ‘squeezing the rock’ of MLR and reducing care ...

Get back to being the insurer of choice for individuals and groups. Contract for the services you need, not own them and try to manage them too. UHG would not be the first insurer who has faced ...

Your Editor recommends grabbing lunch or a cuppa for these lengthy reads/views: Flawed Federal Programs Maroon Rural Americans in Telehealth Blackouts. This is mostly about the billions spent in ‘last ...

One of our Perspectives contributors, Yosi Health, is seeking a Demand Generation Manager for their B2B buyer customers. This role combines lead generation with marketing analysis, coordination with ...

More on this in Strata-gee 15 May. More good news– Editor Ted Green is recuperating and back at his desk, if only part-time. He has been invaluable for his inside looks at Masimo’s endless drama over ...

Most of 23andMe bought for a lot more than one could have thought–and why? Yesterday, the board of 23andMe confirmed that they have a court-approved definitive agreement for the sale of their core ...

Partnerships and add-ons are much in the news this week. Hims & Hers isn’t worrying about GLP-1 drug sourcing. Neither are Ro and LifeMD. All three made a deal with Novo Nordisk on providing branded ...

Medical device company Masimo may not be able to rid itself entirely of its meddlesome former CEO, Joe Kiani. In fact, if a court awards him the shares exercised under his various employment ...

South Australia Health has rolled out Altera Digital Health’s Sunrise Electronic Medical Record (EMR) and Patient Administration System (PAS). The EMR and PAS is being implemented across over 100 ...

Transcarent closes Accolade buy, changes its game. Transcarent’s $621 million acquisition of Accolade was wrapped up in record time (two months from announcement). This takes the Nasdaq-listed ...

There’s a small uptick and some optimism in the air for US digital health deals after all. After a 2024 that realistically was a ‘down round’ or Back To 2019, 2025 is picking its way through the New ...